Potential Lilly drug doubles good cholesterol
Eli Lilly and Co.’s experimental drug doubled levels of good cholesterol in a study, setting up a race with Merck & Co. and Roche Holding AG to develop a new class of medicines to lower heart risk.
Bloomberg News
Articles
Potential Effient rival shows promise in study
A study showing Johnson & Johnson and Bayer AG’s blood-thinner Xarelto succeeded where rival drugs failed could give the companies entry to a $1 billion-plus market where Eli Lilly already competes.
WellPoint eyes $1.5 billion deal for XLHealth
Offers for XLHealth, a provider of managed care for chronically ill Medicare members, may value the company at $1.5 billion to $2 billion.
Cost of Thanksgiving meal jumps 13 percent on food inflation
The cost of a Thanksgiving dinner in the U.S. will jump 13 percent this year, the biggest gain in two decades, as prices rose for everything from turkey to green peas to milk, the American Farm Bureau Federation said.
New York orders WellPoint to make refunds for overcharges
WellPoint is among 11 insurers ordered to refund money to almost 600,000 New Yorkers who were charged too much for health insurance.
Formula One boss embroiled in more controversy
Formula One CEO Bernie Ecclestone’s latest controversies involve bribery allegations and the possible takeover of F1 by News Corp.
Farm-profit volatility boosting risk for lenders, economist says
U.S. farmers face increased financial risk because of higher operating costs and volatile commodity prices, even as income this year reaches a record, said Michael Boehlje, an economist at Purdue University.
Lilly, Amylin agree to end diabetes partnership
Amylin Pharmaceuticals Inc. and Eli Lilly and Co. have agreed to end a decade-long diabetes partnership to resolve litigation. Amylin will make an upfront payment of $250 million to Lilly and future revenue-sharing payments of $1.2 billion plus interest.
Farmland values may extend record, banker chief says
Record-high U.S. farmland values may keep rising as global demand for agricultural products increases, according to S. Joe DeHaven, the chief executive of the Indiana Bankers Association.
Lilly, Bristol-Myers approved to market wider Erbitux use
Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.
Lilly not responsible for Zyprexa user’s death, jury finds
It’s the first verdict in a Zyprexa case since litigation over the antipsychotic drug, the drugmaker’s top seller, began more than eight years ago.
Biggest losers in NFL see bargain opportunity in Luck
The winless Indianapolis Colts and Miami Dolphins are jockeying to land what one former National Football League executive says may be the most valuable—and reasonably priced—top pick in modern draft history.
Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
Lilly loses British Supreme Court ruling over gene patent
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
Ener1 becomes latest energy aid recipient in trouble
Electric-car battery maker Ener1 Inc., whose shares were delisted from the NASDAQ stock market Oct. 28, is the latest recipient of U.S. Energy Department aid to run into financial trouble and draw congressional scrutiny.
Confident automakers adding factory workers
Plants in Indiana and other states are slowly expanding as car companies foresee improved sales due to pent-up demand, population growth and an aging vehicle fleet.
BorgWarner sues Cummins over patents on turbochargers
BorgWarner Inc., the world’s biggest maker of automatic-transmission parts for vehicles, filed a lawsuit accusing Cummins Inc. of infringing on three patents for a titanium wheel used in engine turbochargers.
Lilly pulls Xigris off market after sepsis drug fails study
Eli Lilly and Co. said it will pull its Xigris sepsis drug from all markets after the treatment failed to reduce mortality in a study. The withdrawal may cost Lilly $75 million to $95 million in the fourth quarter.
Simon boosts forecast as quarterly results exceed expectations
Indianapolis-based shopping mall giant Simon Property Group Inc. reported funds from operations that beat analyst estimates and raised its full-year forecast as income from rents rose.
Pacer Foster earns reputation as Buffett of basketball
Indiana Pacer Jeff Foster has played in the NBA for 12 years and earned more than $47 million, and he’s done something extraordinary: He’s saved about three-quarters of his take-home pay.